These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 1931093)
41. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization. Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127 [TBL] [Abstract][Full Text] [Related]
42. Safe use of heparin-coated bypass circuits incorporating a pump-oxygenator. Jones DR; Hill RC; Vasilakis A; Hollingsed MJ; Graeber GM; Gustafson RA; Cruzzavala JL; Murray GF Ann Thorac Surg; 1994 Apr; 57(4):815-8; discussion 818-9. PubMed ID: 8166524 [TBL] [Abstract][Full Text] [Related]
43. Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators. von Segesser LK; Turina M J Thorac Cardiovasc Surg; 1989 Sep; 98(3):386-96. PubMed ID: 2770320 [TBL] [Abstract][Full Text] [Related]
44. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators. Ashraf S; Tian Y; Cowan D; Entress A; Martin PG; Watterson KG Ann Thorac Surg; 1997 Dec; 64(6):1790-4. PubMed ID: 9436574 [TBL] [Abstract][Full Text] [Related]
46. Hemocompatibility of PMEA coated oxygenators used for extracorporeal circulation procedures. Zimmermann AK; Aebert H; Reiz A; Freitag M; Husseini M; Ziemer G; Wendel HP ASAIO J; 2004; 50(3):193-9. PubMed ID: 15171468 [TBL] [Abstract][Full Text] [Related]
47. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Steinberg BM; Grossi EA; Schwartz DS; McLoughlin DE; Aguinaga M; Bizekis C; Greenwald J; Flisser A; Spencer FC; Galloway AC Ann Thorac Surg; 1995 Sep; 60(3):525-9. PubMed ID: 7677475 [TBL] [Abstract][Full Text] [Related]
48. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits. Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955 [TBL] [Abstract][Full Text] [Related]
49. [The evaluation of the bio-compatibility and the clinical usefulness of heparin-coated cardiopulmonary bypass circuits]. Yamanaka J; Takeuchi Y; Torii S; Gomi A; Nakatani H; Kohno K Nihon Kyobu Geka Gakkai Zasshi; 1996 Jan; 44(1):47-53. PubMed ID: 8683171 [TBL] [Abstract][Full Text] [Related]
50. In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass. Ask A; Holt D; Smith L J Extra Corpor Technol; 2006 Mar; 38(1):27-32. PubMed ID: 16637520 [TBL] [Abstract][Full Text] [Related]
51. Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass? Brinks HJ; Weerwind PW; Bogdan S; Verbruggen H; Brouwer MH Perfusion; 2001 Jan; 16(1):3-12. PubMed ID: 11192305 [TBL] [Abstract][Full Text] [Related]
52. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit. Moen O; Fosse E; Bråten J; Andersson C; Høgåsen K; Mollnes TE; Venge P; Kierulf P Perfusion; 1996 Mar; 11(2):113-23. PubMed ID: 8740352 [TBL] [Abstract][Full Text] [Related]